Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on hormones and fertility. Browse all Hormones & Fertility education

Not every man converts testosterone to estrogen at the same rate. Two men with identical testosterone levels can arrive at meaningfully different estradiol concentrations — not because of anything either of them is doing, but because their aromatase enzyme is operating at different genetic speeds. The gene responsible for this variation is CYP19A1, which encodes aromatase, and its polymorphic nature is the direct answer to why aromatase activity varies by genetics. The PlexusDx Precision Peptide Genetic Test analyzes CYP19A1 as part of 14 pathways, 49 peptides, and 150+ genetic insights — placing aromatase variation in the full context of the male hormone system.

What "Polymorphic" Means for an Enzyme Gene

A gene is polymorphic when common variants of that gene exist in the population — variants that alter the gene's sequence without being pathogenic mutations. CYP19A1 is one of the most studied polymorphic genes in the sex hormone field. Its variants fall into two functional categories:

Promoter variants affect how much CYP19A1 is transcribed — how much aromatase protein the cell builds in the first place. CYP19A1 is unusual among cytochrome P450 genes in having multiple tissue-specific promoters: separate regulatory regions control aromatase expression in adipose tissue, bone, placenta, brain, and gonadal tissue. Variants in these promoter regions can increase or decrease expression in specific tissues independently, meaning a CYP19A1 variant might preferentially elevate aromatase activity in peripheral adipose tissue without affecting gonadal expression, or vice versa.

Coding variants affect the structure and catalytic efficiency of the aromatase enzyme itself. These can alter the enzyme's substrate binding affinity (how readily it captures testosterone) or its turnover rate (how quickly it converts substrate to product). A man with a coding variant that produces a more catalytically efficient aromatase will convert more testosterone per enzyme molecule per unit time, regardless of how much enzyme is present.

Well-characterized CYP19A1 variants include rs2414096 and rs727479, both associated with testosterone-to-estradiol ratios in men in published population studies, and the (TTTA)n tetranucleotide repeat in intron 4, which affects tissue-specific aromatase expression. Together, these and related variants produce a continuous spectrum of aromatase activity — not a binary high/low switch.

The Genetic Floor: What Variants Establish Before Lifestyle Enters

CYP19A1 genetics set the baseline conversion rate — the floor of aromatase activity that a man's biology operates from before any lifestyle, body composition, or environmental factor modifies it. This baseline is stable across his lifetime; it doesn't change as he ages, gains or loses weight, or starts a protocol.

What does change around that genetic baseline are the non-genetic amplifiers of aromatase activity:

Adipose tissue volume: Adipose tissue is the primary site of peripheral aromatization in men. More body fat = more aromatase-expressing cells = more substrate conversion, regardless of the per-enzyme rate set by CYP19A1 genetics. A man with high-activity CYP19A1 genetics plus higher adiposity faces compounded aromatase exposure. A man with low-activity genetics can still develop elevated estrogen through adiposity alone.

Age: Aromatase activity increases with age in men. The mechanism involves both increased adipose tissue (common with aging) and age-related changes in aromatase regulation. CYP19A1 genetics shape the baseline; aging shifts the operating point upward from that baseline over time.

Insulin resistance: Elevated insulin and IGF-1 stimulate aromatase expression in adipose tissue. Insulin-resistant men tend toward higher peripheral aromatization independently of CYP19A1 genetics.

Alcohol: Ethanol metabolism stimulates hepatic aromatase activity and increases estrogen concentrations. This is an acute and chronic modifier that stacks on top of the genetic baseline.

The clinical picture that emerges: genetics establishes the rate at which each unit of testosterone substrate is converted by each unit of aromatase enzyme. Body composition, age, insulin status, and lifestyle then determine how much substrate that enzyme encounters and how many cells are expressing it. The interaction between CYP19A1 genetic activity and these non-genetic amplifiers is why two men with similar body composition can still have different estradiol trajectories — and why two men with similar CYP19A1 genetics can end up at different estradiol levels if their body composition and lifestyle differ significantly.

Why Aromatase Variation Matters for Men on Androgen Protocols

When testosterone levels are elevated through any androgen-pathway support strategy, aromatase has more substrate. The genetic conversion rate now operates on a larger pool — amplifying whatever CYP19A1 activity a man carries. A man with high-activity CYP19A1 genetics on an androgen protocol sees his estradiol rise proportionally more steeply than a man with lower-activity genetics, even on identical protocol parameters.

This is why CYP19A1 genetic characterization is one of the most clinically useful pieces of information a provider can have before an androgen protocol begins. It allows:

Anticipation rather than reaction. Rather than waiting to see where estradiol lands after two months on a protocol, a provider with CYP19A1 data can anticipate the estrogen trajectory from the start — building monitoring frequency and intervention thresholds into the protocol design proactively.

Correct interpretation of estrogen lab values. A man with high-activity CYP19A1 genetics who is still within the "normal" estradiol range on a protocol may already be at the top of his genetic tolerance. A man with low-activity genetics can often sustain higher total testosterone without the same estrogen concern. The same lab value reads differently through the CYP19A1 lens.

Understanding the SHBG interaction. Low-SHBG genetics increase free testosterone availability — which means more substrate for aromatase to act on. CYP19A1 genetics and SHBG genetics interact to produce the net free estradiol picture, making it essential to know both. SHBG Genetics: Why Your Free Testosterone Varies covers the binding dimension in context.

CYP19A1 in the Complete Men's Hormone Panel

Aromatase variation is one of six genetic dimensions that together explain why androgen-pathway protocols produce such different results in different men. CYP19A1 is the conversion variable — but it operates within a system that includes SHBG (bioavailability), AR (receptor sensitivity), SRD5A2 (DHT competition), LHCGR/FSHR (HPTA axis), and CYP17A1/CYP11A1 (upstream precursor supply). Understanding why aromatase varies is part of understanding the complete picture — which is why the 6 Reproductive Health insights in the Precision Peptide Genetic Test are designed to be read together, not in isolation.

The deep dive on CYP19A1 as an individual insight is at CYP19A1 and Estrogen Conversion in Men. The four-pathway framework for how genetics affects estrogen in men overall is at How Does Genetics Affect Estrogen in Men? The synthesis of how all six variables interact is at Why TRT Works for Some Men and Not Others: The Genetic Answer. And the complete foundation for the Men's Hormone genetic picture is the Complete Guide to Genetic Men's Hormone Testing.

The Precision Peptide Genetic Test analyzes how your genes influence hormone-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

Ready to understand your CYP19A1 aromatase genetics and how they fit your complete hormone profile? Take the Precision Peptide Genetic Test

Frequently Asked Questions About Aromatase Genetics and CYP19A1

Why does aromatase vary between men?

Aromatase activity varies because CYP19A1 is polymorphic — variants in its promoter and coding regions alter enzyme expression and catalytic efficiency, producing different testosterone-to-estradiol conversion rates between individuals. The Precision Peptide Genetic Test analyzes CYP19A1 as one of 6 Reproductive Health insights within 14 pathways and 150+ genetic insights.

Does adipose tissue affect aromatase independently of genetics?

Yes — adipose tissue is the primary site of peripheral aromatization, and more body fat increases aromatase activity. This modifier operates on top of genetic CYP19A1 baseline. Genetics sets the conversion rate; body composition scales the substrate volume. The Precision Peptide Genetic Test identifies the genetic component as part of 14 pathways, 150+ insights.

How do CYP19A1 genetics interact with SRD5A2 for men on androgen protocols?

CYP19A1 and SRD5A2 compete for the same testosterone substrate — routing it toward estradiol (aromatase) or DHT (5-alpha reductase) respectively. High-activity CYP19A1 diverts more to estrogen; high-activity SRD5A2 diverts more to DHT. The Precision Peptide Genetic Test analyzes both as part of 6 Reproductive Health insights within 14 pathways, 150+ genetic insights.

This article is part of the PlexusDx Education Hub. Browse all Hormones & Fertility education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.